• when it comes to 340B, sentry delivers more

    when it comes to 340B, sentry delivers more. learn why more is needed to meet the compliance challenges of today.

  • Introducing DataNext

    Introducing DataNext

  • Banner image featuring a testimonial from Alexander Mansour

    Alexander Mansour, Director of Finance and 340B Compliance Officer, Henry Ford Ambulatory Pharmacy Services, Testimonial

    “Sentry Data Systems is the undeniable premier leader in 340B compliance solutions. Whether it’s their account managers, their IT team or upper management, they are all very responsive and knowledgeable. I am very pleased to have experienced their dedicat

  • Banner image featuring a whitepaper by Michael J . Sovie, Pharm. D., MBA

    Sentinel ™ Pharmacy Management Infrastructure

    Receive a copy of Sentry’s new comprehensive white paper on contract pharmacy relationships - "340B Contract Pharmacies" by Michael J . Sovie, Pharm. D., MBA

  • Banner image highlighting SentinelRCM, a Revenue Cycle Management solution for hospital pharmacies.

    Sentrex™ Contract Pharmacy Solutions

    Revenue Cycle Management for hospital pharmacies with unprecedented detail that tracks the provider to the patient to the pill to the purchase while delivering integrated audit preparation tools. Find Out More »

  • Banner image featuring Sentrex, a contract pharmacy compliance solution.

    Sentry Puts the Customer First – from Contract signing to 340B Program Audit Support

    Find Out More »

Contact Us to Learn more about 340B Program Compliance and Savings from Sentry

  • What does HRSA’s withdrawal of the 340B mega-reg really mean?

    What does HRSA’s withdrawal of the 340B mega-reg really mean?

    HRSA’s latest action is not so much the end of the story as it is the start of a new chapter. We’ll have to stay tuned to see how it plays ...

    Read More >>

  • The orphan drug exclusion: where do things stand?

    The orphan drug exclusion: where do things stand?

    If you’re confused over the status of the 340B orphan drug exclusion, and how it affects participating free-standing cancer hospitals (CAN), ...

    Read More >>

  • RAND Report clarifies 340B Program impact and provides insights into preserving long-term viability

    RAND Report clarifies 340B Program impact and provides insights into preserving long-term viability

    Last year, Sentry provided support for a recently-published RAND report intended to clarify the 340B Program's purpose, value and extent. The ...

    Read More >>

  • Sentry streamlines 340B program management for pharmacies with their 340B Technology Backbone

    Sentry streamlines 340B program management for pharmacies with their 340B Technology Backbone

    Sentry Data Systems announced today that they’re making available to pharmacies their industry-leading, proprietary 340B platform via a new ...

    Read More >>

  • Annual hospital recertification now underway

    Annual hospital recertification now underway

    All hospitals with an active 340B ID as of July 1 are required to recertify to maintain their 340B eligibility.

    Read More >>